ArticleCell communication and signaling : CCS2026
P2X7 is an important mediator of BMP9-induced osteogenic differentiation of mesenchymal stem cells.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBone morphogenetic protein 9 (BMP9) has been demonstrated to robustly induce osteogenic differentiation of mesenchymal stem cells (MSCs), offering substantial potential for advancements in bone tissue engineering. The purinergic receptor P2X7 has emerged as a crucial modulator of bone formation and bone metabolism. However, the precise role of P2X7 in BMP9-induced osteogenic differentiation of MSCs and the associated molecular mechanisms remain partially understood. This study aims to ascertain the exact function of P2X7 in BMP9-induced osteogenic differentiation of MSCs, and to unravel the relevant molecular mechanism.
methodsTranscriptome sequencing, quantitative real-time polymerase chain reaction, Western blot, and chromatin immunoprecipitation assays were initially performed to validate the up-regulation of P2X7 by BMP9. Subsequently, the influence of P2X7 on BMP9-induced osteogenic differentiation of MSCs was assessed through ALP determination, calcium deposition analysis, Western blotting, ectopic bone formation model, and skull defect model. Finally, the mechanism through which P2X7 modulated BMP9-induced osteogenic differentiation of MSCs was investigated using intracellular Ca2+ imaging, Western blot, molecular docking, immunoprecipitation and immunofluorescence staining.
resultsBMP9 was confirmed to upregulate P2X7 expression via Smad signaling. Activation of P2X7 significantly potentiated BMP9-induced osteogenic differentiation of MSCs and enhanced BMP9-promoted ectopic bone formation, then enhanced the repair of bone defect by BMP9. Conversely, inhibition of P2X7 elicited a contrary effect. Mechanistically, P2X7 activation promoted calcium influx, subsequently leading to the activation of CaMKII by phosphorylation. The activated CaMKII then interacted with GSK-3β, facilitating the inhibitory phosphorylation of GSK-3β at Serine 9 (Ser 9) residue. This may stabilize β-catenin and increase its nuclear translocation, thus finally mediating the osteogenic differentiation of MSCs induced by BMP9.
conclusionThis study clarifies that P2X7 may mediate BMP9-induced osteogenic differentiation of MSCs through the CaMKII/GSK-3β/β-catenin axis, providing novel insights into the molecular mechanism of BMP9-induced osteogenesis and a potential target for bone defect treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.